Linden Capital Partners Acquires Alcresta Therapeutics, Inc.
WALTHAM, Mass., Dec. 5, 2022 /PRNewswire/ -- Alcresta Therapeutics, Inc., a leading commercial-stage company focused on developing and commercializing novel enzyme-based products, today announced that it has moved its corporate headquarters to the Stony Brook Office Park in Waltham, MA. The new facility will combine the company's corporate office personnel, formerly headquartered in Newton, MA, and its research and development laboratory team, formerly based in Natick, MA, at the same location.
NEWTON, Mass., Nov. 29, 2021n/PRNewswire/ -- Alcresta Therapeutics, Inc., a leading commercial-stagencompany focused on developing and commercializing novel, enzyme-based nproducts, announced the appointment of Chris Parrish as its Chief Operations Officer (COO) effective November 29, 2021.
Data from the ASSURE Study of Long-Term Use of RELiZORB® (iMMOBILIZED LIPASE) CARTRIDGE Published in Journal of Pediatric Gastroenterology and Nutrition
Alcresta Therapeutics, Inc. today announced the issuance of a unique Q-code by CMS for its digestive enzyme cartridge RELiZORB. RELiZORB (iMMOBILIZED LIPASE) CARTRIDGE is an in-line digestive enzyme cartridge and is indicated for use in pediatric patients (ages 5 years and above) and adult patients to hydrolyze fats in enteral formula. The code, Q9994, is effective July 1, 2018. CMS has instructed Medicare Administrative Contractors to add Q9994 to the relevant code set as of that date.
Alcresta Therapeutics, Inc., a company dedicated to developing and commercializing novel, enzyme-based products designed to address challenges faced by patients living with gastrointestinal disorders and rare diseases, presented data for the first time from its ASSURE study. This long-term clinical study evaluated the FDA approved RELiZORB® cartridge, an in-line digestive enzyme cartridge, indicated for use in pediatric patients (ages 5 years and above) and adult patients to hydrolyze fats in enteral formula (EF). Data from the ASSURE study was shared at the North American Cystic Fibrosis Conference that took place November 2-4, 2017 in Indianapolis.
Alcresta Therapeutics, Inc. announced RELiZORB has received an Innovative Technology contract from Vizient, Inc. the largest member-driven health care performance improvement company in the country. The awarded contract, effective Sept. 1, 2017, was based on a recommendation of RELiZORB by hospital members who serve on one of Vizient’s member-led councils. Innovative Technology contracts are reserved for technologies that demonstrate an ability to enhance clinical care or patient safety, and those that improve an organization’s care delivery and business model.
Alcresta Therapeutics, Inc., dedicated to developing products designed to address challenges faced by people living with gastrointestinal disorders and rare diseases, announced publication of data from a pivotal clinical study of their product RELiZORB, a novel in-line digestive enzyme cartridge indicated for use in pediatric patients (ages 5 years and above) and adult patients to hydrolyze fats while receiving enteral nutrition.
Alcresta Therapeutics, Inc., dedicated to developing products designed to address nutritional challenges faced by patients with Cystic Fibrosis, Chronic Pancreatitis, Pancreatic Cancer, Gastric Cancer, and other serious diseases, announced that it has received 510(k) clearance from the U.S. Food & Drug Administration (FDA) for its RELiZORB digestive enzyme cartridge for use in pediatric patients suffering from fat malabsorption. RELiZORB was cleared in 2015 for use in patients 18 years and older. This latest clearance will extend the use in children as young as 5 years old.
Bessemer Venture Partners, Frazier Healthcare and Third Rock Ventures have led a $10 million venture capital investment, backing two serial entrepreneurs they've invested with before.